RE:nr-- this makes it now clear the voucher $ is very near...Dumbest pumper every.
Wants to talk about the deal where LMNL sold their only revenue stream (Ryplazim) and gave Kedrion $30M from the sale of the PRV.
All for $5M?? Great move guys.
tommyjones1 wrote: FDA issue voucher has to be settled before closing of deal per NR friday. 2021 is mentioned at large because they dont have the date it will be announced, that easy. Kedrion will want control of their investment and get things rolling now, not in 2022 . It is imminent.
stockbuphoon wrote:
This press release doesn't mean sale of PRV is any closer, you dumba$$. Management guidance was sometime in 2021 and they pay plasma division expenses until they sell it
tommyjones1 wrote:
LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. ("Kedrion") (the "First Closing"). The manufacturing facility is operated through Liminal BioSciences' subsidiary, Prometic Bioproduction Inc. ("PBP").
The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments. Liminal will also be entitled to receive 70% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") by its subsidiary, Prometic Biotherapeutics Inc. ("PBT"), which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT (the "Second Closing"). PBT is the holder of the biological license application ("BLA") for Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). The Second Closing is subject to the fulfilment of certain conditions precedent, including the sale of the PRV by PBT.